David is a Partner in the Health & Life Sciences practice of Oliver Wyman. He has worked extensively with pharmaceutical and biopharma companies, academic research agencies, hospitals, and clinics, as well as providers to and investors in these industries.
Relevant experience:
- Finding $US250 Million in incremental profit for a top 5 pharma company from a drug on the verge of losing patent exclusivity, through a novel targeting and distribution licensing agreement.
- Re-negotiating a drug platform co-development and commercialization licensing agreement between two leading biotech organizations which added a half-billion dollars in NPV to the client.
- Strategizing and building an asthma disease management clinic that increased pharmaceutical revenues +30% among visiting patients, while improving all key clinical factors.
- Developing new non-personal selling models for non-blockbuster drugs at a top-5 pharmaceutical company.
- Negotiating a research funding agreement between a top-3 global pharmaceutical company and a leading academic medical center to develop and operate an integrated health system.
- Developing the strategy, conducting the target searches, and conducting the due diligence, as well as negotiating terms of an acquisition for a private equity firm undertaking a carve-out and consolidation opportunity in the disease management, nurse triage, and health plan member services industries.
- Conducting due diligence for a private equity fund interested in acquiring a Workers’ Compensation focused Third-Party Administrator (TPA), which involved deep assessment of regulatory and coverage environments by state, as well as a detailed review of the procedures and systems of the target company.
- For a leading hospital system, developing turnaround strategies for clinics that had undergone substantial regulatory reimbursement cuts. The strategy, which was implemented and delivered results above expectations, changed the clinic from serving only a local catchment area, to one that began to serve nationally and internationally.
David has addressed conferences of healthcare executives in both North America and Europe. He recently co-authored "Licensing to Win" and "Beyond a Shadow of a Drought," two white papers on the state of the biopharma industry's licensing and R&D opportunities. Prior to joining Oliver Wyman, David was an Engineer with IBM, a Brand Manager with Procter & Gamble, and practiced strategy consulting with another global management consultancy.
He holds an Honours Bachelor of Applied Science in Electrical Engineering from Queen’s University at Kingston, Canada, where he co-developed a biomedical device for neuro-muscular disease diagnoses as his engineering thesis.